Citations 1
A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies.
Ansell, Stephen M. , Chen, Robert W., Maris, Michael B., O’Connor, Owen A. , Wieland, Elizabeth, Flinn, Ian W. , Sievers, Eric L.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7585-TPS7585
